- cafead   Jul 13, 2023 at 11:42: AM
via Roche is pushing deeper into synthetic lethality. One year after paying $125 million to join the ATR race, the Swiss drug developer has secured an exclusive global license to KSQ Therapeutics’ early-phase USP1 inhibitor.
article source
article source